CombinatoRx (CRXX) Presents Full Data on Synavive Phase 2 Knee OA Trial at EULAR 2009
Tweet Send to a Friend
CombinatoRx, Incorporated (NASDAQ: CRXX) announced the presentation of full data on Synavive (CRx-102) Phase 2 knee osteoarthritis (OA) trial (COMET-1) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
